<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04930744</url>
  </required_header>
  <id_info>
    <org_study_id>AUR1-1-199</org_study_id>
    <secondary_id>1U01AI134585-01A1</secondary_id>
    <nct_id>NCT04930744</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)</brief_title>
  <acronym>METHOD</acronym>
  <official_title>A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aurum Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>A*STAR Infectious Diseases Labs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The METHOD study will examine whether adding metformin to standard antibiotic treatment for&#xD;
      tuberculosis (TB) in people with HIV is safe and well tolerated. The study will also test if&#xD;
      adding metformin clears the infection more quickly and with less lung damage. When enrolled,&#xD;
      participants will have an equal chance of being in the group that takes standard TB medicines&#xD;
      alone or in the group that also takes metformin. Participants will have a chance to be put on&#xD;
      either: 1) standard TB medicines (isoniazid, rifampicin, ethambutol and pyrazinamide for two&#xD;
      months, continuing isoniazid and rifampin for four more months) only; or 2) the same standard&#xD;
      TB medicines plus metformin. Participants randomized to the metformin arm will take metformin&#xD;
      for eleven weeks, starting one week after starting the standard TB medicines. In addition to&#xD;
      monitoring for side effects, all participants will have studies of drug levels and lung and&#xD;
      immune function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The METHOD trial is a Phase II A randomized, open-label trial of metformin added to standard&#xD;
      anti-tuberculosis treatment (ATT) and anti-retroviral therapy (ART) in TB/HIV co-infected&#xD;
      patients. HIV-positive adults (treated or ART-naïve) newly diagnosed with sputum&#xD;
      culture-positive, drug-sensitive pulmonary TB will be recruited to and enrolled in the study.&#xD;
      All participants in the interventional study will take standard ATT for drug-sensitive&#xD;
      pulmonary TB starting at enrollment. Participants in the metformin arm will begin taking&#xD;
      metformin 1 week later and metformin will be stopped on week-12. The &quot;omics&quot; control group&#xD;
      will include those (treated or ART-naïve) without evidence of active TB. The total cohort is&#xD;
      sample size N=112, comprising 56 participants each in two parallel study arms (standard&#xD;
      therapy or standard therapy plus metformin) with the goal of retaining 100 participants with&#xD;
      evaluable data for analysis. The duration of the METHOD trial is 5 years. The duration of&#xD;
      individual participation in the interventional arms of the study is 36 weeks, not including&#xD;
      an initial period of screening over an interval of up to 7 additional days prior to study&#xD;
      enrollment. The final clinic visit coincides with the completion of ATT at week-24. The final&#xD;
      follow-up contact is a phone interview at week-36. Ten consenting participants from each&#xD;
      study arm (n=20 total) will have intensive pharmacokinetic/pharmacodynamic (PK/PD) sampling.&#xD;
      The remaining 92 participants will have sparse PK/PD sampling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are assigned to one of two or more groups, Standard ATT or Standard ATT plus Metformin in parallel for 11 weeks starting 1 week after ATT initiation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Senior study leadership, Drs. Kornfeld, Wallis, Churchyard, Singhal will be blinded. Participants, study personnel and clinicians are not blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of metformin as measured by the number of grade 3 or higher gastrointestinal (GI) adverse events</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Average and median numbers of Grade 3, 4 and 5 adverse events will be tabulated by treatment arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metformin added to standard ATT improves respiratory health as measured by radiographic score</measure>
    <time_frame>Change in baseline radiographic score at week 24</time_frame>
    <description>Between arm differences of change in radiographic score will be tabulated by arm and time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin added to standard ATT improves respiratory health as measured by 6-minute Walk Test (6MWT) as assessed by distance x 02 saturation (2° endpoint)</measure>
    <time_frame>Change in baseline 6MWT at week 24</time_frame>
    <description>Between arm differences of change in 6MWT distance oxygen saturation will be tabulated by arm and time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin added to standard ATT improves respiratory health as measured by spirometry: Forced Vital Capacity (FVC)</measure>
    <time_frame>Change in baseline spirometric value at week 24</time_frame>
    <description>Between arm differences of change in spirometric values will be tabulated by arm and time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin added to standard ATT improves respiratory health as measured by spirometry: Forced Expiratory Volume (FEV1%) (2° endpoint)</measure>
    <time_frame>Change in baseline spirometric value at week 24</time_frame>
    <description>Between arm differences of change in spirometric values will be tabulated by arm and time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin added to standard ATT improves respiratory health as measured by Saint George's Respiratory Questionnaire (SGRQ) assessed by 2° endpoint</measure>
    <time_frame>Change in baseline SGRQ at week 24</time_frame>
    <description>Between arm differences of change in SGRQ score will be tabulated by arm and timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin added to standard ATT improves HIV outcomes as measured by HIV viral load</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Between-arm differences of HIV viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin added to standard ATT improves HIV outcomes as measured by CD4</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Between-arm differences in CD4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin added to standard ATT improves HIV outcomes as measured by T cell count</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Between-arm differences of T cell count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin added to standard ATT improves TB treatment outcomes</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Between arm differences will be tabulated in the secondary endpoints of cure, failure, death, default, and relapse.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Efficacy of metformin as measured by time to sputum conversion in Mycobacterial Growth Indicator Tube (MGIT)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Sputum liquid culture conversion will be tabulated by treatment arm</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Tuberculosis</condition>
  <condition>Pulmonary Tuberculosis</condition>
  <condition>HIV Coinfection</condition>
  <arm_group>
    <arm_group_label>Standard Tuberculosis Medicine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will have a chance to be put on standard tuberculosis medicines (Isoniazid, Rifampicin, Ethambutol and Pyrazinamide) only. It is a combination pill pack that will be taken by mouth daily. The combination pack includes Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide which they will take for 2 months. They will only take Isoniazid and Rifampicin for the last 4 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard TB Medicines and Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will have a chance to be put on standard tuberculosis medicines (Isoniazid, Rifampicin, Ethambutol and Pyrazinamide) only. It is a combination pill pack that will be taken by mouth daily. The combination pack includes Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide which they will take for 2 months. They will only take Isoniazid and Rifampicin for the last 4 months. For this arm, they will also take Metformin hydrochloride one 500 mg tablet daily starting one week after the initiation of tuberculosis medicines, then increasing to one 500 mg table twice daily through study week-12 for a total 11 weeks of metformin exposure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid</intervention_name>
    <description>Isoniazid, dose prescribed by participant's physician, will be taken by mouth daily. Isoniazid, is in a combination pill pack with the other standard ATT medications.</description>
    <arm_group_label>Standard TB Medicines and Metformin</arm_group_label>
    <arm_group_label>Standard Tuberculosis Medicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>Rifampicin, dose prescribed by participant's physician, will be taken by mouth daily. Rifampicin is in a combination pill pack with the other standard ATT medications.</description>
    <arm_group_label>Standard TB Medicines and Metformin</arm_group_label>
    <arm_group_label>Standard Tuberculosis Medicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethambutol</intervention_name>
    <description>Ethambutol, dose prescribed by participant's physician, will be taken by mouth daily. Ethambutol is in a combination pill pack with the other standard ATT medications.</description>
    <arm_group_label>Standard TB Medicines and Metformin</arm_group_label>
    <arm_group_label>Standard Tuberculosis Medicine</arm_group_label>
    <other_name>Myambutol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrazinamide</intervention_name>
    <description>Pyrazinamide, dose prescribed by participant's physician, will be taken by mouth daily. Pyrazinamide is in a combination pill pack with the other standard ATT medications.</description>
    <arm_group_label>Standard TB Medicines and Metformin</arm_group_label>
    <arm_group_label>Standard Tuberculosis Medicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin hydrochoride</intervention_name>
    <description>Metformin hydrochloride 500 mg tablet once daily starting one week after the initiation of TB treatment, then increasing to study twice daily through study week-12 (11 weeks total metformin treatment).</description>
    <arm_group_label>Standard TB Medicines and Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-1 seropositive status prior to or after screening.&#xD;
&#xD;
          -  Chest radiograph compatible with pulmonary TB&#xD;
&#xD;
          -  Positive sputum pert TB/Rifampicin (RIF) with one Ct&lt;25 or subsequent culture&#xD;
             confirmation&#xD;
&#xD;
          -  RIF susceptibility diagnosed by GeneXpert MTB/RIF&#xD;
&#xD;
          -  Residence within study catchment area&#xD;
&#xD;
          -  If female of childbearing potential, willing to use contraception for the duration of&#xD;
             study participation&#xD;
&#xD;
          -  Able and willing to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any condition for which participation in the trial, as judged by the investigator,&#xD;
             could compromise the well-being of the participant or prevent, limit or confound&#xD;
             protocol-specified assessments.&#xD;
&#xD;
          -  Is critically ill, and in the judgment of the investigator has a diagnosis likely to&#xD;
             result in death during the trial or the follow-up period.&#xD;
&#xD;
          -  TB meningitis or other forms of severe TB with high risk of a poor outcome as judged&#xD;
             by the investigator.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Resistance to any first-line ATT drug demonstrated by susceptibility testing.&#xD;
&#xD;
          -  More than 7 days ATT for the current episode of TB, prior to enrollment.&#xD;
&#xD;
          -  Taking an ART regimen that contains Dolutegravir (DTG).&#xD;
&#xD;
          -  Taking any fluoroquinolone antibiotic.&#xD;
&#xD;
          -  Minimally advanced pulmonary TB on chest x-ray (NTRDA criteria).&#xD;
&#xD;
          -  History of diabetes mellitus or fasting blood glucose ≥7.0 mmol/L on screening&#xD;
             evaluation.&#xD;
&#xD;
          -  History of congestive heart failure, chronic liver disease, autoimmune disease or&#xD;
             malignancy.&#xD;
&#xD;
          -  Consumption of &gt;28 units (men) OR &gt;21 units (women) of alcohol/week&#xD;
&#xD;
          -  Use of metformin within 1 year prior to enrollment.&#xD;
&#xD;
          -  History of sensitivity to metformin.&#xD;
&#xD;
          -  Acute or chronic metabolic acidosis based on reported medical history or laboratory&#xD;
             tests performed on screening evaluation.&#xD;
&#xD;
          -  Body mass index (BMI) &lt;17.0 kg/m2 on screening evaluation.&#xD;
&#xD;
          -  Peripheral blood Cluster Differentiation 4 (CD4) T cell count &lt;200 cells/mm3 on&#xD;
             screening evaluation.&#xD;
&#xD;
          -  Hemoglobin &lt;10 g/dL on screening evaluation.&#xD;
&#xD;
          -  Platelet count &lt;50,000/mm3 on screening evaluation.&#xD;
&#xD;
          -  Absolute neutrophil count &lt;750 cells/mm3 on screening evaluation.&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m2 calculated by the&#xD;
             chronic kidney disease epidemiology (CKD-EPI) equation.&#xD;
&#xD;
          -  Serum bicarbonate &lt;20 mmol/L on screening evaluation.&#xD;
&#xD;
          -  Asparate aminotransferase (AST or ALT) ≥3 times the upper limit of normal (ULN) on&#xD;
             screening evaluation.&#xD;
&#xD;
          -  Anti-hepatitis B surface antigen or hepatitis C virus seropositive.&#xD;
&#xD;
          -  Imprisonment at the time of or after enrollment in the METHOD trial.&#xD;
&#xD;
          -  Diagnosis of active COVID-19 at time of screening or high suspicion of active&#xD;
             Coronavirus disease of 2019 (COVID-19) disease during screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Participant eligibility is based on self-representation of gender identity.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert S Wallis, MD, FIDSA</last_name>
    <role>Study Chair</role>
    <affiliation>Aurum Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hardy Kornfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Massachusetts Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Modulakgotla Sebe, MBCHB</last_name>
    <phone>+27 87 135 1645</phone>
    <email>msebe@auruminstitute.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lerato Mngomezulu, BNSC</last_name>
    <phone>+27 87 135 1560</phone>
    <email>lmgnomezulu@auruminstitute.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tembisa Clinical Research Centre-The Aurum Institute</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1632</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mondulakgotla A Sebe, MBCHB</last_name>
      <phone>+27 61 430 3117</phone>
      <email>msebe@auruminstitute.org</email>
    </contact>
    <contact_backup>
      <last_name>Lerato Mngomezulu</last_name>
      <phone>+27 73 817 1725</phone>
      <email>lmngomezulu@auruminstitute.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <reference>
    <citation>Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, Gitta P, Okwera A, Mugerwa RD, Alcaneses MR, Quelapio MI, Tupasi TE, Horter L, Debanne SM, Eisenach KD, Boom WH. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med. 2009 Sep 15;180(6):558-63. doi: 10.1164/rccm.200904-0536OC. Epub 2009 Jun 19.</citation>
    <PMID>19542476</PMID>
  </reference>
  <reference>
    <citation>Pasipanodya JG, McNabb SJ, Hilsenrath P, Bae S, Lykens K, Vecino E, Munguia G, Miller TL, Drewyer G, Weis SE. Pulmonary impairment after tuberculosis and its contribution to TB burden. BMC Public Health. 2010 May 19;10:259. doi: 10.1186/1471-2458-10-259.</citation>
    <PMID>20482835</PMID>
  </reference>
  <reference>
    <citation>Abdool Karim SS, Churchyard GJ, Karim QA, Lawn SD. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet. 2009 Sep 12;374(9693):921-33. doi: 10.1016/S0140-6736(09)60916-8. Epub 2009 Aug 24. Review.</citation>
    <PMID>19709731</PMID>
  </reference>
  <reference>
    <citation>Singhal A, Jie L, Kumar P, Hong GS, Leow MK, Paleja B, Tsenova L, Kurepina N, Chen J, Zolezzi F, Kreiswirth B, Poidinger M, Chee C, Kaplan G, Wang YT, De Libero G. Metformin as adjunct antituberculosis therapy. Sci Transl Med. 2014 Nov 19;6(263):263ra159. doi: 10.1126/scitranslmed.3009885.</citation>
    <PMID>25411472</PMID>
  </reference>
  <reference>
    <citation>Lachmandas E, Eckold C, Böhme J, Koeken VACM, Marzuki MB, Blok B, Arts RJW, Chen J, Teng KWW, Ratter J, Smolders EJ, Van den Heuvel C, Stienstra R, Dockrell HM, Newell E, Netea MG, Singhal A, Cliff JM, Van Crevel R. Metformin Alters Human Host Responses to Mycobacterium tuberculosis in Healthy Subjects. J Infect Dis. 2019 Jun 5;220(1):139-150. doi: 10.1093/infdis/jiz064.</citation>
    <PMID>30753544</PMID>
  </reference>
  <reference>
    <citation>Degner NR, Wang JY, Golub JE, Karakousis PC. Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment. Clin Infect Dis. 2018 Jan 6;66(2):198-205. doi: 10.1093/cid/cix819.</citation>
    <PMID>29325084</PMID>
  </reference>
  <reference>
    <citation>Kumar NP, Moideen K, Viswanathan V, Shruthi BS, Sivakumar S, Menon PA, Kornfeld H, Babu S. Elevated levels of matrix metalloproteinases reflect severity and extent of disease in tuberculosis-diabetes co-morbidity and are predominantly reversed following standard anti-tuberculosis or metformin treatment. BMC Infect Dis. 2018 Jul 25;18(1):345. doi: 10.1186/s12879-018-3246-y.</citation>
    <PMID>30045688</PMID>
  </reference>
  <reference>
    <citation>Padmapriyadarsini C, Bhavani PK, Natrajan M, Ponnuraja C, Kumar H, Gomathy SN, Guleria R, Jawahar SM, Singh M, Balganesh T, Swaminathan S. Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial. BMJ Open. 2019 Mar 1;9(3):e024363. doi: 10.1136/bmjopen-2018-024363.</citation>
    <PMID>30826761</PMID>
  </reference>
  <reference>
    <citation>Sheth SH, Larson RJ. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis. 2010 Jun 23;10:183. doi: 10.1186/1471-2334-10-183.</citation>
    <PMID>20573187</PMID>
  </reference>
  <reference>
    <citation>Ralph AP, Kenangalem E, Waramori G, Pontororing GJ, Sandjaja, Tjitra E, Maguire GP, Kelly PM, Anstey NM. High morbidity during treatment and residual pulmonary disability in pulmonary tuberculosis: under-recognised phenomena. PLoS One. 2013 Nov 29;8(11):e80302. doi: 10.1371/journal.pone.0080302. eCollection 2013.</citation>
    <PMID>24312209</PMID>
  </reference>
  <reference>
    <citation>Ralph AP, Ardian M, Wiguna A, Maguire GP, Becker NG, Drogumuller G, Wilks MJ, Waramori G, Tjitra E, Sandjaja, Kenagalem E, Pontororing GJ, Anstey NM, Kelly PM. A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis. Thorax. 2010 Oct;65(10):863-9. doi: 10.1136/thx.2010.136242.</citation>
    <PMID>20861290</PMID>
  </reference>
  <reference>
    <citation>Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010 Apr 14;(4):CD002967. doi: 10.1002/14651858.CD002967.pub4. Review.</citation>
    <PMID>20393934</PMID>
  </reference>
  <reference>
    <citation>Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011 Feb;50(2):81-98. doi: 10.2165/11534750-000000000-00000. Review.</citation>
    <PMID>21241070</PMID>
  </reference>
  <reference>
    <citation>Chandel NS, Avizonis D, Reczek CR, Weinberg SE, Menz S, Neuhaus R, Christian S, Haegebarth A, Algire C, Pollak M. Are Metformin Doses Used in Murine Cancer Models Clinically Relevant? Cell Metab. 2016 Apr 12;23(4):569-70. doi: 10.1016/j.cmet.2016.03.010.</citation>
    <PMID>27076070</PMID>
  </reference>
  <reference>
    <citation>Song IH, Zong J, Borland J, Jerva F, Wynne B, Zamek-Gliszczynski MJ, Humphreys JE, Bowers GD, Choukour M. The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects. J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):400-7. doi: 10.1097/QAI.0000000000000983.</citation>
    <PMID>26974526</PMID>
  </reference>
  <reference>
    <citation>Te Brake LHM, Yunivita V, Livia R, Soetedjo N, van Ewijk-Beneken Kolmer E, Koenderink JB, Burger DM, Santoso P, van Crevel R, Alisjahbana B, Aarnoutse RE, Ruslami R; TANDEM Consortium. Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients. Clin Pharmacol Ther. 2019 Mar;105(3):730-737. doi: 10.1002/cpt.1232. Epub 2018 Oct 29.</citation>
    <PMID>30222857</PMID>
  </reference>
  <reference>
    <citation>Grün B, Kiessling MK, Burhenne J, Riedel KD, Weiss J, Rauch G, Haefeli WE, Czock D. Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters. Br J Clin Pharmacol. 2013 Nov;76(5):787-96. doi: 10.1111/bcp.12079.</citation>
    <PMID>23305245</PMID>
  </reference>
  <reference>
    <citation>Wulffelé MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJ, Stehouwer CD. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med. 2003 Nov;254(5):455-63.</citation>
    <PMID>14535967</PMID>
  </reference>
  <reference>
    <citation>Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf. 2010 Sep 1;33(9):727-40. doi: 10.2165/11536790-000000000-00000. Review.</citation>
    <PMID>20701406</PMID>
  </reference>
  <reference>
    <citation>Booysen HL, Woodiwiss AJ, Raymond A, Sareli P, Hsu HC, Dessein PH, Norton GR. Chronic kidney disease epidemiology collaboration-derived glomerular filtration rate performs better at detecting preclinical end-organ changes than alternative equations in black Africans. J Hypertens. 2016 Jun;34(6):1178-85. doi: 10.1097/HJH.0000000000000924.</citation>
    <PMID>27035736</PMID>
  </reference>
  <reference>
    <citation>DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: Current perspectives on causes and risk. Metabolism. 2016 Feb;65(2):20-9. doi: 10.1016/j.metabol.2015.10.014. Epub 2015 Oct 9. Review.</citation>
    <PMID>26773926</PMID>
  </reference>
  <reference>
    <citation>Brackett CC. Clarifying metformin's role and risks in liver dysfunction. J Am Pharm Assoc (2003). 2010 May-Jun;50(3):407-10. doi: 10.1331/JAPhA.2010.08090. Review.</citation>
    <PMID>20452916</PMID>
  </reference>
  <reference>
    <citation>Wallis RS, Peppard T. Early Biomarkers and Regulatory Innovation in Multidrug-Resistant Tuberculosis. Clin Infect Dis. 2015 Oct 15;61Suppl 3:S160-3. doi: 10.1093/cid/civ612.</citation>
    <PMID>26409278</PMID>
  </reference>
  <reference>
    <citation>Hoft DF, Worku S, Kampmann B, Whalen CC, Ellner JJ, Hirsch CS, Brown RB, Larkin R, Li Q, Yun H, Silver RF. Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity. J Infect Dis. 2002 Nov 15;186(10):1448-57. Epub 2002 Oct 23.</citation>
    <PMID>12404160</PMID>
  </reference>
  <reference>
    <citation>Wallis RS, Wang C, Meyer D, Thomas N. Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model. PLoS One. 2013 Aug 5;8(8):e71116. doi: 10.1371/journal.pone.0071116. Print 2013. Review.</citation>
    <PMID>23940699</PMID>
  </reference>
  <reference>
    <citation>Wester CW, Eden SK, Shepherd BE, Bussmann H, Novitsky V, Samuels DC, Hendrickson SL, Winkler CA, O'Brien SJ, Essex M, D'Aquila RT, DeGruttola V, Marlink RG. Risk factors for symptomatic hyperlactatemia and lactic acidosis among combination antiretroviral therapy-treated adults in Botswana: results from a clinical trial. AIDS Res Hum Retroviruses. 2012 Aug;28(8):759-65. doi: 10.1089/AID.2011.0303. Epub 2012 Jun 1.</citation>
    <PMID>22540188</PMID>
  </reference>
  <reference>
    <citation>Aperis G, Paliouras C, Zervos A, Arvanitis A, Alivanis P. Lactic acidosis after concomitant treatment with metformin and tenofovir in a patient with HIV infection. J Ren Care. 2011 Mar;37(1):25-9. doi: 10.1111/j.1755-6686.2011.00209.x.</citation>
    <PMID>21288314</PMID>
  </reference>
  <reference>
    <citation>Ortiz-Brizuela E, Pérez-Patrigeon S, Recillas-Gispert C, Gómez-Pérez FJ. Lactic Acidosis Complicating Metformin and Non-Nucleoside Reverse Transcriptase Inhibitor Combination Therapy: A Smoldering Threat in the Post-HAART Era. Rev Invest Clin. 2015 Jul-Aug;67(4):273-4.</citation>
    <PMID>26426594</PMID>
  </reference>
  <reference>
    <citation>Hashim H, Sahari NS, Sazlly Lim SM, Hoo FK. Fatal Tenofovir-Associateacd Lactic Acidosis: A Case Report. Iran Red Crescent Med J. 2015 Oct 24;17(10):e19546. doi: 10.5812/ircmj.19546. eCollection 2015 Oct.</citation>
    <PMID>26568856</PMID>
  </reference>
  <reference>
    <citation>Naccarato M, Yoong D, Fong IW. Dolutegravir and metformin: a case of hyperlactatemia. AIDS. 2017 Sep 24;31(15):2176-2177. doi: 10.1097/QAD.0000000000001617.</citation>
    <PMID>28906282</PMID>
  </reference>
  <reference>
    <citation>Cho SK, Yoon JS, Lee MG, Lee DH, Lim LA, Park K, Park MS, Chung JY. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther. 2011 Mar;89(3):416-21. doi: 10.1038/clpt.2010.266. Epub 2011 Jan 26.</citation>
    <PMID>21270793</PMID>
  </reference>
  <reference>
    <citation>Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, Elliott JH, Murdoch D, Wilkinson RJ, Seyler C, John L, van der Loeff MS, Reiss P, Lynen L, Janoff EN, Gilks C, Colebunders R; International Network for the Study of HIV-associated IRIS. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008 Aug;8(8):516-23. doi: 10.1016/S1473-3099(08)70184-1.</citation>
    <PMID>18652998</PMID>
  </reference>
  <reference>
    <citation>Doyle MA, Singer J, Lee T, Muir M, Cooper C. Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. Trials. 2016 Jul 20;17(1):331. doi: 10.1186/s13063-016-1454-6.</citation>
    <PMID>27439433</PMID>
  </reference>
  <reference>
    <citation>Cameron AR, Morrison VL, Levin D, Mohan M, Forteath C, Beall C, McNeilly AD, Balfour DJ, Savinko T, Wong AK, Viollet B, Sakamoto K, Fagerholm SC, Foretz M, Lang CC, Rena G. Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status. Circ Res. 2016 Aug 19;119(5):652-65. doi: 10.1161/CIRCRESAHA.116.308445. Epub 2016 Jul 14.</citation>
    <PMID>27418629</PMID>
  </reference>
  <reference>
    <citation>Lazarus B, Wu A, Shin JI, Sang Y, Alexander GC, Secora A, Inker LA, Coresh J, Chang AR, Grams ME. Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study. JAMA Intern Med. 2018 Jul 1;178(7):903-910. doi: 10.1001/jamainternmed.2018.0292.</citation>
    <PMID>29868840</PMID>
  </reference>
  <reference>
    <citation>Moyo S, Bussmann H, Mangwendeza P, Dusara P, Gaolathe T, Mine M, Musonda R, van Widenfelt E, Novitsky V, Makhema J, Marlink RG, Essex M, Wester CW. Validation of A Point-of-Care Lactate Device For Screening At-Risk Adults Receiving Combination Antiretroviral Therapy In Botswana. J Antivir Antiretrovir. 2011 Oct;3(4):45-48. Epub 2011 Sep 20.</citation>
    <PMID>23087782</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Hardy Kornfeld, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>Anti-Tuberculosis Treatment (ATT)</keyword>
  <keyword>Anti-Viral Therapy (ART)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
    <mesh_term>Coinfection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The plan is to share the standard operating procedures, the study protocol, the informed consent form, and the data collection tools. Research data that document, support and validate research findings will be made available after the main findings from the final research data set have been accepted for publication. The trial also includes a plan to collect and store genomic DNA. Written informed consent is obtained indicating consent for their genomic and phenotypic data to be used for future research purposes and to be shared broadly in a de-identified manner. Institutional certification has been obtained. Data generated from this trial, including genomic data and associated data, will be submitted to an NIH-designated repository such as database of Genotype and Phenotype (dbGaP).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data generated by this investigation will be made publicly available no later than six months after the initial data submission to NIH or at the time of the first publication, whichever occurs first.</ipd_time_frame>
    <ipd_access_criteria>Following publication of research data, may be shared upon request by contacting the study principal investigators by email.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

